Prof. Andrea Alimonti, head of Molecular Oncology at the Institute of Oncology Research is a full professor at Università della Svizzera italiana, at the University of Padova and at ETH Zurich, and an ERC and J. Steiner Cancer Research awarded clinical research scientist.
Prof. Alimonti received his MD degree from the University of Rome "La Sapienza" and his medical and training in oncology from the National Cancer Institute of Rome. Prof. Alimonti completed a postdoctoral fellowship in cancer biology in the laboratory of PP Pandolfi first at Memorial Sloan-Kettering Cancer Center in New York and then at Harvard Medical School in Boston. In 2010 he joined the Institute of Oncology Research in Switzerland, as head of the Molecular Oncology Group. Prof. Alimonti has won several prestigious awards and grants such as the Swiss Bridge Award, the J Steiner Cancer Research Award, the EMBO YIP and the European Research Council (ERC) starting and consolidator grants. He is the author of many clinical and basic research publications in major scientific journals (e.g. Nature, Cell, Nat. Gen etc).
The major scientific contributions of Prof. Alimonti research include the identification of the relevance of “quasi-insufficiency” in cancer initiation and the discovery of a novel pro-senescence approach to cancer therapy based on immunotherapy. Prof. Alimoti overall vision is to develop state-of-the-art innovative treatments for patients affected by cancer. Some of these treatments are currently tested in the clinic by Prof. Alimonti's team.